SG10202004557QA - Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 - Google Patents

Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9

Info

Publication number
SG10202004557QA
SG10202004557QA SG10202004557QA SG10202004557QA SG10202004557QA SG 10202004557Q A SG10202004557Q A SG 10202004557QA SG 10202004557Q A SG10202004557Q A SG 10202004557QA SG 10202004557Q A SG10202004557Q A SG 10202004557QA SG 10202004557Q A SG10202004557Q A SG 10202004557QA
Authority
SG
Singapore
Prior art keywords
cas9
crispr
tracking
cellular rna
rna via
Prior art date
Application number
SG10202004557QA
Other languages
English (en)
Inventor
Gene Yeo
David Nelles
Mark Fang
Ranjan Batra
Original Assignee
Univ California
Mark Fang
Ranjan Batra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Mark Fang, Ranjan Batra filed Critical Univ California
Publication of SG10202004557QA publication Critical patent/SG10202004557QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG10202004557QA 2015-11-23 2016-11-22 Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 SG10202004557QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562259014P 2015-11-23 2015-11-23

Publications (1)

Publication Number Publication Date
SG10202004557QA true SG10202004557QA (en) 2020-06-29

Family

ID=57750540

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201804372PA SG11201804372PA (en) 2015-11-23 2016-11-22 Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
SG10202004557QA SG10202004557QA (en) 2015-11-23 2016-11-22 Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201804372PA SG11201804372PA (en) 2015-11-23 2016-11-22 Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9

Country Status (10)

Country Link
US (4) US20170145394A1 (pt)
EP (2) EP4163374A1 (pt)
JP (2) JP2019500899A (pt)
CN (1) CN109072235B (pt)
AU (1) AU2016359629B2 (pt)
CA (1) CA3005968A1 (pt)
ES (1) ES2930643T3 (pt)
PT (1) PT3380613T (pt)
SG (2) SG11201804372PA (pt)
WO (1) WO2017091630A1 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3313989A4 (en) 2015-06-29 2018-12-05 Ionis Pharmaceuticals, Inc. Modified crispr rna and modified single crispr rna and uses thereof
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and their uses
SG11201804372PA (en) * 2015-11-23 2018-06-28 Univ California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
JP2019530464A (ja) 2016-10-14 2019-10-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのａａｖ送達
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
EP3622062A4 (en) 2017-05-10 2020-10-14 The Regents of the University of California DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN111344020A (zh) 2017-06-15 2020-06-26 加利福尼亚大学董事会 靶向非病毒dna插入
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
US11970720B2 (en) 2017-08-22 2024-04-30 Salk Institute For Biological Studies RNA targeting methods and compositions
US10476825B2 (en) 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
AU2018352592A1 (en) 2017-10-16 2020-06-04 Beam Therapeutics, Inc. Uses of adenosine base editors
CA3079727A1 (en) * 2017-10-24 2019-05-02 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of rare diseases
KR102503130B1 (ko) 2017-10-27 2023-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 내인성 t 세포 수용체의 표적화된 대체
CN107893260B (zh) * 2017-11-27 2021-01-12 广州市锐博生物科技有限公司 高效去除核糖体rna的构建转录组测序文库的方法及试剂盒
CN108103090B (zh) * 2017-12-12 2021-06-15 中山大学附属第一医院 靶向RNA甲基化的RNA Cas9-m6A修饰载体系统及其构建方法和应用
CN108559760A (zh) * 2018-01-09 2018-09-21 陕西师范大学 基于CRISPR靶向基因组修饰技术建立荧光素酶knock-in细胞系的方法
FI3765616T3 (fi) * 2018-03-14 2023-08-29 Arbor Biotechnologies Inc Uusia CRISPR-DNA- ja RNA-kohdennusentsyymejä ja -järjestelmiä
DK3765615T3 (da) 2018-03-14 2023-08-21 Arbor Biotechnologies Inc Nye enzymer og systemer til målretning af crispr dna
EP3810273A4 (en) * 2018-05-15 2022-03-16 The Children's Hospital of Philadelphia HTT ALLELE REMOVAL BASED ON CRISPR INTERFERENCE AND TREATMENT OF HUNTINGTON'S DISEASE
WO2019222555A1 (en) 2018-05-16 2019-11-21 Arbor Biotechnologies, Inc. Novel crispr-associated systems and components
EP3575401A1 (en) * 2018-05-29 2019-12-04 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of treating or preventing an aging-related disease
SG11202012015YA (en) * 2018-06-08 2021-01-28 Locanabio Inc Compositions and methods for the modulation of adaptive immunity
WO2019236982A1 (en) 2018-06-08 2019-12-12 Locana, Inc. Rna-targeting fusion protein compositions and methods for use
JP2021531038A (ja) * 2018-07-13 2021-11-18 ザ、トラスティーズ オブ プリンストン ユニバーシティ ストレス顆粒集合を調節するためのシステム及び方法
US20210388351A1 (en) * 2018-09-28 2021-12-16 The Jackson Laboratory Artificial rna-guided splicing factors
CN109706149B (zh) * 2018-11-29 2020-12-18 华中农业大学 一种改进的16S-seq方法及其应用
RU2694396C1 (ru) * 2018-12-14 2019-07-12 Федеральное Бюджетное Учреждение Науки "Центральный Научно-Исследовательский Институт Эпидемиологии" Федеральной Службы По Надзору В Сфере Защиты Прав Потребителей И Благополучия Человека РНК-проводник St10 для использования в высокоспецифической системе нуклеаз Streptococcus thermophilus CRISPR/Cas9 (StCas9) и применение указанного РНК-проводника и белка StCas9 для подавления экспрессии вируса гепатита B в клетке-хозяине и для элиминации вирусной ДНК из клетки-хозяина
CN113544267A (zh) * 2019-01-14 2021-10-22 罗切斯特大学 使用CRISPR-Cas进行靶向核RNA裂解和聚腺苷酸化
WO2020160125A1 (en) * 2019-01-29 2020-08-06 Flagship Pioneering Innovations V, Inc. Compositions comprising an endonuclease and methods for purifying an endonuclease
LU101118B1 (en) 2019-02-06 2020-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Method for detecting a specific splice event of a gene of interest
CN109811072B (zh) * 2019-02-28 2022-05-06 广州微远医疗器械有限公司 用于结核分枝杆菌复合群的crispr检测引物组及其用途
EP3942040A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN110004181B (zh) * 2019-03-20 2022-10-11 东北农业大学 一种附加型CRISPR/Cas9表达载体及其构建方法与应用
WO2020198640A1 (en) * 2019-03-27 2020-10-01 Massachusetts Institute Of Technology Programmable imaging methods and compositions
CN110714008A (zh) * 2019-10-17 2020-01-21 南通大学 核苷酸序列构建的crispr重组质粒靶向编辑iss序列的方法
AU2020394910A1 (en) * 2019-12-02 2022-06-23 Council Of Scientific & Industrial Research Method and kit for detection of polynucleotide
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
GB202105455D0 (en) 2021-04-16 2021-06-02 Ucl Business Ltd Composition
EP4095243A1 (en) * 2021-05-25 2022-11-30 European Molecular Biology Laboratory System for hybridization-based precision genome cleavage and editing, and uses thereof
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2023129973A2 (en) * 2021-12-30 2023-07-06 Eclipse Bioinnovations, Inc. Methods for detecting rna modification targets on a gene
WO2023205637A1 (en) * 2022-04-18 2023-10-26 Locanabio, Inc. Rna-targeting compositions and methods for treating c9/orf72 diseases
CN115044620B (zh) * 2022-06-30 2024-01-05 上海海洋大学 微卫星重复序列敲除突变体的构建方法和应用
CN117925787A (zh) * 2024-01-17 2024-04-26 北京医院 基于“内-外”双重信号放大的DCasFISH染色体多色原位成像系统

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
BR9106729A (pt) 1990-08-03 1993-07-20 Sterling Winthrop Inc Composto,processos para inibir a degradacao por nuclease de compostos e para estabilizar sequencias de nicleotideos ou oligonucleosideos,composicao utilizavel para inibir expressao de genes e processo para inibir expressao de genes em um mamifero necessitando de tal tratamento
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
JPH08508491A (ja) 1993-03-31 1996-09-10 スターリング ウインスロップ インコーポレイティド ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
KR100414936B1 (ko) 1997-09-12 2004-01-13 엑시콘 에이/에스 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체
WO1999053017A2 (en) 1998-04-15 1999-10-21 Fred Hutchinson Cancer Research Center Methods and vector constructs for making transgenic non-human animals which ubiquitously express a heterologous gene
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
JP2002543214A (ja) 1999-05-04 2002-12-17 エクシコン エ／エス Ｌ−リボ−ｌｎａ類縁体
IL149694A0 (en) 1999-12-23 2002-11-10 Exiqon As Therapeutic uses of lna-modified oligonucleotides
CA2402452A1 (en) 2000-03-31 2001-10-11 Cambridge Antibody Technology Limited Improvements to ribosome display
JP5405312B2 (ja) 2007-11-22 2014-02-05 独立行政法人科学技術振興機構 低分子ｒｎａによる細胞または人工細胞モデルでの翻訳制御システム
WO2012068627A1 (en) 2010-11-24 2012-05-31 The University Of Western Australia Peptides for the specific binding of rna targets
WO2012093422A1 (ja) 2011-01-07 2012-07-12 坂東機工株式会社 炭化珪素板のスクライブ方法及びスクライブ装置
JP6164488B2 (ja) 2011-10-21 2017-07-19 国立大学法人九州大学 Ｐｐｒモチーフを利用したｒｎａ結合性蛋白質の設計方法及びその利用
JP6317675B2 (ja) * 2011-11-30 2018-04-25 サレプタ セラピューティクス， インコーポレイテッド 延長リピート病を処置するためのオリゴヌクレオチド
EP2819788B1 (en) 2012-02-27 2018-08-22 Amunix Operating Inc. Xten conjugate compositions and methods of making same
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2013359212B2 (en) * 2012-12-12 2017-01-19 Massachusetts Institute Of Technology Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
MX2015007550A (es) 2012-12-12 2017-02-02 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
AU2014207618A1 (en) * 2013-01-16 2015-08-06 Emory University Cas9-nucleic acid complexes and uses related thereto
TWI484033B (zh) 2013-01-25 2015-05-11 Univ China Medical 培養幹細胞之方法及套組
AU2014265331B2 (en) * 2013-05-15 2019-12-05 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
CA2913869C (en) * 2013-05-29 2023-01-24 Cellectis New compact scaffold of cas9 in the type ii crispr system
EP3004349B1 (en) * 2013-05-29 2018-03-28 Cellectis S.A. A method for producing precise dna cleavage using cas9 nickase activity
US10329587B2 (en) * 2013-07-10 2019-06-25 President And Fellows Of Harvard College Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
JP2016528897A (ja) 2013-08-16 2016-09-23 ラナ セラピューティクス インコーポレイテッド Ｒｎａを調節するための組成物および方法
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US10822606B2 (en) * 2013-09-27 2020-11-03 The Regents Of The University Of California Optimized small guide RNAs and methods of use
US9074199B1 (en) 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
CN106029880A (zh) * 2013-12-12 2016-10-12 布罗德研究所有限公司 核苷酸重复障碍中CRISPR-Cas系统的组合物和使用方法
US9994831B2 (en) 2013-12-12 2018-06-12 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
PL3115457T3 (pl) 2014-03-05 2020-01-31 National University Corporation Kobe University Sposób modyfikacji sekwencji genomowej do specyficznego przekształcania zasad kwasu nukleinowego docelowej sekwencji dna oraz kompleks molekularny do zastosowania w nim
CN105338513B (zh) 2014-08-08 2019-12-10 中兴通讯股份有限公司 设备到设备业务处理方法及装置
RU2711506C2 (ru) 2014-12-17 2020-01-17 ПРОКЬЮЭР ТЕРАПЬЮТИКС II Би.Ви. Редактирование целевой рнк
WO2016106236A1 (en) * 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
US10330674B2 (en) 2015-01-13 2019-06-25 Massachusetts Institute Of Technology Pumilio domain-based modular protein architecture for RNA binding
WO2016183402A2 (en) 2015-05-13 2016-11-17 President And Fellows Of Harvard College Methods of making and using guide rna for use with cas9 systems
US20180148711A1 (en) 2015-05-28 2018-05-31 Coda Biotherapeutics, Inc. Genome editing vectors
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
WO2016196805A1 (en) 2015-06-05 2016-12-08 The Regents Of The University Of California Methods and compositions for generating crispr/cas guide rnas
US20160362667A1 (en) 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
WO2016201138A1 (en) 2015-06-12 2016-12-15 The Regents Of The University Of California Reporter cas9 variants and methods of use thereof
EP3323890A4 (en) 2015-07-14 2019-01-30 Fukuoka University METHOD FOR INDUCING SITE SPECIFIC RNA MUTATIONS, TARGET EDITION GUIDING RNA-GUIDE USED IN THE METHOD, AND TARGET EDITING GUID-RNA TARGET RNA COMPLEX
US20180237800A1 (en) 2015-09-21 2018-08-23 The Regents Of The University Of California Compositions and methods for target nucleic acid modification
CN116751827B (zh) 2015-09-21 2024-01-30 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
SG11201804372PA (en) 2015-11-23 2018-06-28 Univ California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
AU2017283713B2 (en) 2016-06-17 2021-04-08 Massachusetts Institute Of Technology Type VI CRISPR orthologs and systems
LT6525B (lt) 2016-06-29 2018-05-10 Uab Pixpro Skaitmeninių vaizdų skyros didinimo būdas taikant unikalų dalinai persidengiančių mažos skyros vaizdų apdorojimą
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
EP3585895A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Compositions and methods for gene editing
KR102357045B1 (ko) 2017-03-31 2022-01-28 뉴로디아그노스틱스 엘엘씨 알츠하이머 질환에 대한 림프구-기반 형태계측 시험
EP3622062A4 (en) 2017-05-10 2020-10-14 The Regents of the University of California DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9
US11168322B2 (en) 2017-06-30 2021-11-09 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
US10476825B2 (en) 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions
KR102338449B1 (ko) 2017-09-21 2021-12-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
CN108103090B (zh) 2017-12-12 2021-06-15 中山大学附属第一医院 靶向RNA甲基化的RNA Cas9-m6A修饰载体系统及其构建方法和应用
WO2019126762A2 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
US20220127621A1 (en) 2018-04-20 2022-04-28 The Regents Of The University Of California Fusion proteins and fusion ribonucleic acids for tracking and manipulating cellular rna
US20210340197A1 (en) 2018-08-31 2021-11-04 The Regents Of The University Of California Directed pseudouridylation of rna
WO2020047498A1 (en) 2018-08-31 2020-03-05 The Regents Of The University Of California Directed modification of rna
CN110055284A (zh) 2019-04-15 2019-07-26 中山大学 一种基于PspCas13b-Alkbh5单基因特异性m6A修饰编辑方法
WO2020214830A1 (en) 2019-04-16 2020-10-22 The Regents Of The University Of California Protein translational control

Also Published As

Publication number Publication date
PT3380613T (pt) 2022-12-02
CN109072235B (zh) 2023-02-28
JP2019500899A (ja) 2019-01-17
US20230365951A1 (en) 2023-11-16
AU2016359629B2 (en) 2023-03-09
WO2017091630A4 (en) 2017-08-24
EP3380613B1 (en) 2022-10-26
ES2930643T3 (es) 2022-12-20
JP2022081503A (ja) 2022-05-31
SG11201804372PA (en) 2018-06-28
WO2017091630A1 (en) 2017-06-01
EP3380613A1 (en) 2018-10-03
US20200239863A1 (en) 2020-07-30
US20190040370A1 (en) 2019-02-07
US20170145394A1 (en) 2017-05-25
AU2016359629A1 (en) 2018-06-07
EP4163374A1 (en) 2023-04-12
CA3005968A1 (en) 2017-06-01
US11667903B2 (en) 2023-06-06
CN109072235A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
SG10202004557QA (en) Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
EP3622062A4 (en) DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9
IL290678A (en) New crispr enzymes and systems
HK1258288A1 (zh) 核酸酶非依賴性靶向基因編輯平台及其用途
SG11202001208XA (en) Rna targeting methods and compositions
IL259100A (en) Therapeutic targets for human dystrophin gene repair through gene editing and methods for use
EP3374494A4 (en) CRISPR COMPOSITIONS AND METHODS OF USE FOR GENE THERAPY
HK1253674A1 (zh) 用於具有增强的穩定性的瞬時基因療法的組合物和方法
EP3307762A4 (en) CAS9 REPORTER VARIANTS AND METHODS OF USE
EP3313989A4 (en) Modified crispr rna and modified single crispr rna and uses thereof
EP3359644A4 (en) NOVEL RNA-GUIDED NUCLEASES AND USES THEREOF
EP3397757A4 (en) NEW TRANSPOSASES ASSOCIATED WITH CRISPR AND USES THEREOF
EP3303634A4 (en) CASE VARIANTS9 AND METHODS OF USE THEREOF
EP3362104A4 (en) METHODS AND COMPOSITIONS USING CPF1 FOR RNA-GUIDED GENETIC EDITION
IL250744A0 (en) A method for preparing flavociclib and its pharmaceutical preparations
EP3245232A4 (en) Heterodimeric cas9 and methods of use thereof
GB201510296D0 (en) Thermostable CAS9 nucleases
HK1254608A1 (zh) 改良的地拉羅司製劑及其製備方法
ZA201900225B (en) Methods and compositions for gene expression in plants
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
GB201519128D0 (en) Solid forms and methods of preparing the same
HK1252778A1 (zh) 細胞擴增方法和治療組合物
IL255178B (en) Strigolactones or their derivatives for use in increasing the yield of a cultivated plant
SG11201705450SA (en) Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
HK1247136A1 (zh) 包含15-hepe的組合物和其使用方法